First report on the safety and efficacy of an extended half‐life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A

N8‐GP (turoctocog alfa pegol) is an extended half‐life glycoPEGylated recombinant factor VIII (FVIII) product developed for the prevention and treatment of bleeds in haemophilia A patients.

[1]  J. Oldenburg,et al.  Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A , 2016, Thrombosis and Haemostasis.

[2]  B. Abbuehl,et al.  Efficacy and safety of pegylated full‐length recombinant factor VIII with extended half‐life for perioperative haemostasis in haemophilia A patients , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  J. Oldenburg,et al.  Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  A. Savic,et al.  Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  S. Ehrenforth.  n8-gp - a new long-acting factor Viii for the treatment of patients with haemophilia A , 2014 .

[6]  G. Mariani,et al.  Inhibitors to factor VII in congenital factor VII deficiency , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  K. Haddley.  Turoctocog alfa for the treatment of hemophilia A. , 2014, Drugs of today.

[8]  D. Viuff,et al.  Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A , 2013, Journal of thrombosis and haemostasis : JTH.

[9]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  S. Arkin,et al.  BDDrFVIII (Moroctocog alfa [AF‐CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  R. Schutgens,et al.  Co‐morbidity in the ageing haemophilia patient: the down side of increased life expectancy , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  C. Négrier,et al.  Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients , 2008, Thrombosis and Haemostasis.

[13]  I. Hvid,et al.  Surgery in hemophilia. The general view: patient selection, timing, and preoperative assessment. , 2006, Seminars in hematology.

[14]  Masoud Parsania,et al.  THE PATIENTS , 1982, California state journal of medicine.